Clinical Trial Update: Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy

View source ↗

Summary

This clinical trial update from Adaptive Biotechnologies aims to optimize ctDNA-based minimal residual disease assessment in patients with follicular lymphoma, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Mantle Cell Lymphoma

Drugs mentioned

• CAR-T cell therapy

Snippet

Sponsor: Adaptive Biotechnologies | Conditions: Follicular Lymphoma, Diffuse Large B Cell Lymphoma | Status: RECRUITING